Following results that have sent the stock northward, Research Capital analyst Andre Uddin remains bullish on Eupraxia ...

Eupraxia Pharmaceuticals shares rose in premarket trading Tuesday after the company said it received positive data from its eosinophilic esophagitis treatment trials. Shares traded nearly 6.3% higher ...

Eupraxia Pharmaceuticals Inc. shares T.EPRX are trading unchanged at $5.33.

Eupraxia Pharmaceuticals (EPRX) announced additional positive clinical data from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Deficiency of 25-hydroxyvitamin D at age 3 years is associated with more than double the risk for eosinophilic asthma in ...

Imagine returning from a dream vacation, only to find yourself battling a mysterious illness that leaves doctors baffled. For ...

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $12 price ...

Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.

Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.

Researchers are tackling neutrophilic asthma, successfully developing one of the first mouse models of the condition.

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...